Zhang Chen, Zaman Lubaba A, Poluektova Larisa Y, Gorantla Santhi, Gendelman Howard E, Dash Prasanta K
Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Pathogens. 2023 Jun 27;12(7):879. doi: 10.3390/pathogens12070879.
A major roadblock to achieving a cure for human immunodeficiency virus type one (HIV-1) is the persistence of latent viral infections in the cells and tissue compartments of an infected human host. Latent HIV-1 proviral DNA persists in resting memory CD4+ T cells and mononuclear phagocytes (MPs; macrophages, microglia, and dendritic cells). Tissue viral reservoirs of both cell types reside in the gut, lymph nodes, bone marrow, spleen, liver, kidney, skin, adipose tissue, reproductive organs, and brain. However, despite the identification of virus-susceptible cells, several limitations persist in identifying broad latent reservoirs in infected persons. The major limitations include their relatively low abundance, the precise identification of latently infected cells, and the lack of biomarkers for identifying latent cells. While primary MP and CD4+ T cells and transformed cell lines are used to interrogate mechanisms of HIV-1 persistence, they often fail to accurately reflect the host cells and tissue environments that carry latent infections. Given the host specificity of HIV-1, there are few animal models that replicate the natural course of viral infection with any precision. These needs underlie the importance of humanized mouse models as both valuable and cost-effective tools for studying viral latency and subsequently identifying means of eliminating it. In this review, we discuss the advantages and limitations of humanized mice for studies of viral persistence and latency with an eye toward using these models to test antiretroviral and excision therapeutics. The goals of this research are to use the models to address how and under which circumstances HIV-1 latency can be detected and eliminated. Targeting latent reservoirs for an ultimate HIV-1 cure is the task at hand.
实现治愈人类免疫缺陷病毒1型(HIV-1)的一个主要障碍是潜伏性病毒感染在受感染人类宿主的细胞和组织隔室中持续存在。潜伏的HIV-1前病毒DNA存在于静止的记忆CD4+T细胞和单核吞噬细胞(MPs;巨噬细胞、小胶质细胞和树突状细胞)中。这两种细胞类型的组织病毒库存在于肠道、淋巴结、骨髓、脾脏、肝脏、肾脏、皮肤、脂肪组织、生殖器官和大脑中。然而,尽管已经确定了对病毒敏感的细胞,但在识别受感染个体中的广泛潜伏库方面仍然存在一些限制。主要限制包括它们相对较低的丰度、潜伏感染细胞的精确识别以及缺乏用于识别潜伏细胞的生物标志物。虽然原代MP和CD4+T细胞以及转化细胞系用于探究HIV-1持续存在的机制,但它们往往无法准确反映携带潜伏感染的宿主细胞和组织环境。鉴于HIV-1的宿主特异性,几乎没有动物模型能够精确复制病毒感染的自然过程。这些需求凸显了人源化小鼠模型作为研究病毒潜伏并随后确定消除病毒潜伏方法的有价值且具有成本效益的工具的重要性。在这篇综述中,我们讨论了人源化小鼠在病毒持续存在和潜伏研究中的优点和局限性,着眼于使用这些模型来测试抗逆转录病毒和切除疗法。这项研究的目标是利用这些模型来解决如何以及在何种情况下可以检测和消除HIV-1潜伏。针对潜伏库以最终治愈HIV-1是当前的任务。